Nocturia Drugs in Development Research Report 2022: Pipeline Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

Nocturia Drugs in Development Research Report 2022: Pipeline Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com




Nocturia Drugs in Development Research Report 2022: Pipeline Landscape, Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nocturia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

This pipeline guide provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 3 and 2 respectively.

Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Report Coverage

Overview

Therapeutics Development

  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies

Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Companies Involved in Therapeutics Development

  • Ferring International Center SA
  • Ferring Research Institute Inc
  • Tacurion Pharma Inc
  • Wellesley Pharmaceuticals LLC

Drug Profiles

  • (acetaminophen + ibuprofen) – Drug Profile
  • ASP-7035 – Drug Profile
  • desmopressin acetate ODT – Drug Profile
  • FE-201836 – Drug Profile
  • Synthetic Peptide 1 to Agonise Vasopressin V2 Receptor for Nocturia – Drug Profile
  • Synthetic Peptide to Agonise Vasopressin V2 Receptor for Nocturia – Drug Profile

Dormant Projects

Discontinued Products

Product Development Milestones

Featured News & Press Releases

  • Nov 09, 2018: NOCDURNA (desmopressin acetate) sublingual tablets now available by prescription in US for treatment of nocturia due to nocturnal polyuria
  • Aug 08, 2017: Ferring Pharmaceuticals: The Scottish Medicines Consortium Approves Use of NOQDIRNA (oral lyophilisate desmopressin), the First Licensed Treatment for Nocturia due to Idiopathic Nocturnal Polyuria in Adults
  • Aug 07, 2017: Noqdirna is accepted for restricted use within NHS Scotland
  • Feb 13, 2017: Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/jrrs19

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900